Among studies on gemcitabine resistance in pancreatic cancer, it has been reported that cancer genes c-Src and bcl-XL, and the proinflammatory NF-κB signaling pathway are closely related to gemcitabine resistance 19-21. The gene discussed is BCL2L1; the disease is pancreatic neoplasm.